Overall Group 1 Group 2 P value
Median [IQR] or Number (%) Mean [IQR] or Number (%) Mean [IQR] or Number (%)
Sternal wound infection 0 0 0 -
Re-exploration for bleeding/tamponade 1% (2/178) 1% (1/90) 1% (1/88) 0.482
Renal replacement therapy 2.8% (5/178) 1.1% (1/90) 4.6% (4/88) 0.351
Cerebrovascular accident Permanent stroke TIA 5.0% (9/178) 2.2% (4/178) 2.8% (5/178) 6.6% (6/90) 3.3% (3/90) 3.3% (3/90) 3.4% (3/88) 1.1% (1/88) 2.3% (2/88) 0.519 0.629 0.979
LOS median [IQR] (days) 10 [7 – 14] 9 [7 – 13] 12 [8 – 15] 0.179
LOS > 30 days 7.3% (13/178) 5.6% (5/90) 9.1% (8/88) 0.365
Composite outcome* 19.1% (34/178) 14.4% (13/90) 23.8% (21/88) 0.110
Permanent pacemaker Pre discharge Post discharge 7.8% (14/178) 2.2% (4/178) 5.6% (10/178) 3.3% (3/90) 2.2% (2/90) 1.1% (1/90) 12.5% (11/88) 2.2% (2/88) 10.2% (9/88) 0.046 0.629 0.021
Overall in-hospital mortality LIMA patency Injury at the re-entry LIMA injury 7.8% (14/178) 7.8% (10/127) 23.8% (5/21) 16.6% (2/12) 5.5% (5/90) 4.3% (3/69) 0 0 10.2% (9/88) 12.0% (7/58) 29.4% (5/17) 20.0% (2/10) 0.247 0.201 0.555 0.729
Group 1 – re-sternotomy for isolated aortic valve replacement with patent coronary grafts Group 2 – re-sternotomy for aortic valve replacement +/- other concomitant cardiac procedure with patent coronary grafts LIMA – Left Internal Mammary Artery, LOS – Length of Stay * Composite of in-hospital mortality, postoperative TIA/stroke, renal failure requiring new hemofiltration, deep sternal wound infection, re-exploration for bleeding/tamponade and length of stay >30 days Group 1 – re-sternotomy for isolated aortic valve replacement with patent coronary grafts Group 2 – re-sternotomy for aortic valve replacement +/- other concomitant cardiac procedure with patent coronary grafts LIMA – Left Internal Mammary Artery, LOS – Length of Stay * Composite of in-hospital mortality, postoperative TIA/stroke, renal failure requiring new hemofiltration, deep sternal wound infection, re-exploration for bleeding/tamponade and length of stay >30 days Group 1 – re-sternotomy for isolated aortic valve replacement with patent coronary grafts Group 2 – re-sternotomy for aortic valve replacement +/- other concomitant cardiac procedure with patent coronary grafts LIMA – Left Internal Mammary Artery, LOS – Length of Stay * Composite of in-hospital mortality, postoperative TIA/stroke, renal failure requiring new hemofiltration, deep sternal wound infection, re-exploration for bleeding/tamponade and length of stay >30 days Group 1 – re-sternotomy for isolated aortic valve replacement with patent coronary grafts Group 2 – re-sternotomy for aortic valve replacement +/- other concomitant cardiac procedure with patent coronary grafts LIMA – Left Internal Mammary Artery, LOS – Length of Stay * Composite of in-hospital mortality, postoperative TIA/stroke, renal failure requiring new hemofiltration, deep sternal wound infection, re-exploration for bleeding/tamponade and length of stay >30 days Group 1 – re-sternotomy for isolated aortic valve replacement with patent coronary grafts Group 2 – re-sternotomy for aortic valve replacement +/- other concomitant cardiac procedure with patent coronary grafts LIMA – Left Internal Mammary Artery, LOS – Length of Stay * Composite of in-hospital mortality, postoperative TIA/stroke, renal failure requiring new hemofiltration, deep sternal wound infection, re-exploration for bleeding/tamponade and length of stay >30 days